1. Home
  2. SAFE vs EVO Comparison

SAFE vs EVO Comparison

Compare SAFE & EVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Safehold Inc. New

SAFE

Safehold Inc. New

HOLD

Current Price

$14.96

Market Cap

1.1B

Sector

Real Estate

ML Signal

HOLD

Logo Evotec SE

EVO

Evotec SE

HOLD

Current Price

$2.90

Market Cap

1.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SAFE
EVO
Founded
2016
1993
Country
United States
Germany
Employees
N/A
4553
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.1B
1.1B
IPO Year
1999
N/A

Fundamental Metrics

Financial Performance
Metric
SAFE
EVO
Price
$14.96
$2.90
Analyst Decision
Hold
Strong Buy
Analyst Count
10
1
Target Price
$19.00
$7.00
AVG Volume (30 Days)
290.5K
45.0K
Earning Date
04-30-2026
04-08-2026
Dividend Yield
4.48%
N/A
EPS Growth
7.43
N/A
EPS
0.40
N/A
Revenue
$385,552,000.00
N/A
Revenue This Year
N/A
$1.37
Revenue Next Year
$4.31
$10.05
P/E Ratio
$37.75
N/A
Revenue Growth
5.43
N/A
52 Week Low
$12.76
$2.31
52 Week High
$17.16
$4.42

Technical Indicators

Market Signals
Indicator
SAFE
EVO
Relative Strength Index (RSI) 50.65 47.56
Support Level $14.70 $2.88
Resistance Level $15.31 $3.82
Average True Range (ATR) 0.35 0.06
MACD 0.04 0.01
Stochastic Oscillator 70.40 56.12

Price Performance

Historical Comparison
SAFE
EVO

About SAFE Safehold Inc. New

Safehold Inc is a REIT that operates its business by acquiring, managing, and capitalizing ground leases. Ground leases are long-term contracts between the landlord (the Company) and a tenant or leaseholder. Ground leases generally represent ownership of the land underlying commercial real estate projects that are net leased by the fee owner of the land to the owners/operators of the real estate projects built thereon.

About EVO Evotec SE

Evotec SE is a life science company focused on developing pharmaceutical products through standalone services, integrated R&D programs, and strategic partnerships with pharmaceutical and biotechnology companies, academic institutions, and other partners. It operates across drug discovery, preclinical development, and manufacturing, with expertise in areas including oncology, central nervous system, cardiovascular-renal, immune and inflammatory, infectious, and other diseases. The Company generates revenue through fee-for-service and FTE-based services, milestones, and royalties, and equity ownership in biotechnology and academic projects. It operates through the Shared R&D and Discovery & Preclinical Development (D&PD) segments, with the majority of revenue generated from the USA.

Share on Social Networks: